Selank and semax for ADHD focus: what the science actually says

What did @taylorleoniefit actually say?

She didn't make a hard medical claim. She described a chaotic post-gym afternoon where she forgot her Amazon package, ran in circles trying to multitask, and couldn't focus long enough to get a simple task done. Her conclusion: "you just have undiagnosed ADHD more than likely." She also mentioned doing "peptide injections" in passing, and her hashtags point to Selank and Semax as the likely compounds involved. That's actually a fairly restrained presentation. She's not saying these peptides cured anything. She's using her own scattered behavior as a punchline and a self-diagnostic moment.

The video is more of a personal vlog than a medical tutorial, which matters for how we evaluate it. But the hashtag combo of #selank, #semax, and #adhdprobs implies a connection between these compounds and her attention issues, even if she never states it outright. That implied connection is worth examining carefully.

Does the science back this up?

There is legitimate preclinical and some early clinical research on both Semax and Selank, but calling it robust would be a stretch. Most of it comes from Russian research institutions, involves small sample sizes, and hasn't been replicated in large Western trials. That doesn't make it worthless, but it does mean the evidence base is genuinely thin.

Semax is a synthetic analog of ACTH(4-7) and has been studied primarily for neuroprotection and cognitive function. A 2014 study by Dolotov et al. published in the Journal of Molecular Neuroscience showed Semax increased BDNF levels in rat models. BDNF dysregulation has been linked to ADHD symptomology in some research, including work by Shim et al. (2016, Psychiatry Investigation). Selank is a synthetic analog of tuftsin and has shown anxiolytic effects in animal models, with one small Russian clinical trial by Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) suggesting reduced anxiety without sedation. Neither compound has an FDA-approved indication for ADHD. Implying these peptides address her "undiagnosed ADHD" goes well beyond what the current evidence supports.

What did they get wrong (or right)?

Let's give credit where it's due. She didn't claim Semax or Selank treats ADHD directly. She described her own behavior and made an offhand self-diagnosis, which, while not medically sound, is not the same as claiming a peptide is a cure. That restraint matters.

What she got wrong, or at least muddled, is the implied framing. Tagging a chaotic, distracted afternoon with #selank, #semax, and #adhdprobs while mentioning she just did her peptide injections creates an obvious inference for viewers: these peptides are helping her manage ADHD-like symptoms. That's an implied therapeutic claim that isn't backed by clinical evidence in humans. Self-diagnosing ADHD based on a disorganized afternoon is also genuinely problematic. ADHD diagnosis requires standardized assessment tools (like the Conners Rating Scale or DIVA-5 interview), clinician evaluation, and ruling out other causes. A forgettable protein powder delivery is not a diagnostic criterion.

Her characterization of the behavior itself, racing between tasks, forgetting things mid-action, being unable to complete a linear sequence, does loosely describe executive dysfunction. But executive dysfunction shows up in sleep deprivation, stress, thyroid issues, and dozens of other conditions. Jumping straight to "undiagnosed ADHD" skips over a lot of important ground.

What should you actually know?

Semax and Selank are not approved by the FDA for any indication. In the United States, they exist in a regulatory gray area, typically compounded by specialty pharmacies for off-label use under a clinician's supervision. Anyone seeing these compounds promoted on TikTok should know that the evidence base is preliminary, largely animal-based, and sourced primarily from Russian literature that hasn't been independently replicated at scale.

If you genuinely think you have ADHD, the path forward is a proper clinical evaluation, not a peptide injection stack. Actual ADHD treatment options with strong evidence include stimulant medications (amphetamine salts, methylphenidate) and non-stimulants (atomoxetine, guanfacine), alongside behavioral therapy. Amen et al. (2021, Journal of Attention Disorders) and the AHRQ's comparative effectiveness review both document this evidence clearly.

Using peptides without a prescriber's oversight also carries real risks: injection site reactions, unknown long-term effects, sourcing quality concerns, and drug interactions that haven't been studied. This isn't fearmongering. It's just the actual state of the evidence in 2024.